Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.56 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.56 |
| ▸ | EPHX1 | P07099 | 8/20 | 0.51 |
| ▸ | RRM1 | P23921 | 1/20 | 0.47 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.47 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.45 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.45 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.45 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | CPT2 | P23786 | 1/20 | 0.43 |
| ▸ | CPT1A | P50416 | 1/20 | 0.43 |
| ▸ | CPT1B | Q92523 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20543106 | 1.00 | SIRT6 (0.56) | SIRT6SIRT1EPHX1RRM1DPP7 | |
| SCHEMBL20542683 | 1.00 | SIRT6 (0.56) | SIRT6SIRT1EPHX1RRM1DPP7 | |
| SCHEMBL20543104 | 1.00 | SIRT6 (0.56) | SIRT6SIRT1EPHX1RRM1DPP7 | |
| SCHEMBL20542644 | 1.00 | SIRT6 (0.56) | SIRT6SIRT1EPHX1RRM1DPP7 | |
| SCHEMBL20543146 | 1.00 | SIRT6 (0.56) | SIRT6SIRT1EPHX1RRM1DPP7 | |
| SCHEMBL20542738 | 1.00 | SIRT6 (0.56) | SIRT6SIRT1EPHX1RRM1DPP7 | |
| SCHEMBL20542995 | 1.00 | SIRT6 (0.56) | SIRT6SIRT1EPHX1RRM1DPP7 | |
| SCHEMBL20542642 | 1.00 | SIRT6 (0.56) | SIRT6SIRT1EPHX1RRM1DPP7 | |
| SCHEMBL20542681 | 1.00 | SIRT6 (0.56) | SIRT6SIRT1EPHX1RRM1DPP7 | |
| SCHEMBL20542740 | 1.00 | SIRT6 (0.56) | SIRT6SIRT1EPHX1RRM1DPP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180311342-A1 | IMMUNOSTIMULATING AGENT | AJINOMOTO CO., INC. (JP) | 2018-11-01 | — | — | US | claimed |
| EP-3395365-A1 | IMMUNOSTIMULATING AGENT | AJINOMOTO CO., INC. (JP) | 2018-10-31 | — | — | EP | claimed |
| US-20180311342-A1 | IMMUNOSTIMULATING AGENT | AJINOMOTO CO., INC. (JP) | 2018-11-01 | — | — | US | disclosed |
| EP-3395365-A1 | IMMUNOSTIMULATING AGENT | AJINOMOTO CO., INC. (JP) | 2018-10-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180311342-A1 | IMMUNOSTIMULATING AGENT | MYD88, TLR9, IL2 | SIRT6 1830/4885SIRT1 1226/4885EPHX1 2378/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.